Levothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: In thyroid cancer, high levothyroxine (LT4) doses may reflect intentional thyroid-stimulating hormone (TSH) suppression rather than impaired bioavailability. We assessed gastrointestinal and medication-related factors in relation to LT4 dose after accounting for treatment goals and body mass index (BMI). Methods: This cross-sectional study included 218 LT4-treated patients and 69 non-LT4 reference patients. A structured questionnaire captured gastrointestinal symptoms, comorbidities, medications, and administration timing. BMI was calculated from recorded height and weight. The main adjusted analysis was restricted to participants with clinician-assessed target achievement; exploratory models additionally used measured TSH categories. Multivariable models used HC3 robust standard errors. Results: Among LT4-treated patients, 201 (92.2%) had thyroid cancer, 81 (37.2%) reported gastrointestinal symptoms, 74 (33.9%) had at least one potential interfering factor, and 49 (22.5%) reported proton-pump inhibitor (PPI) use. Factor prevalence was comparable in the reference population after adjustment for age, sex, and BMI. In the BMI-adjusted model (n = 156), PPI use was not associated with higher LT4 dose (β = −0.031 µg/kg/day, 95% CI −0.193 to 0.131; p = 0.703). Intended TSH suppression was associated with higher dose (β = 0.420, 95% CI 0.269–0.570; p < 0.001), whereas BMI was inversely associated with dose per kilogram. An exploratory BMI-adjusted model accounting for measured TSH categories also showed no significant association with PPI exposure (n = 184, β = 0.024 µg/kg/day, 95% CI −0.122 to 0.169; p = 0.751). Conclusions: Potentially interfering factors were common but were not independently associated with higher dose requirements. LT4 dose in thyroid cancer should be interpreted in relation to therapeutic intent and anthropometry; PPI exposure alone was not a reliable marker of increased dose requirement.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229032
Authors: Wadim Bowl(Data curation, Formal analysis, Methodology, Writing – original draft), Anne-Sophie Schmidt(Data curation, Writing – review & editing), Conrad-Amadeus Voltin(Writing – review & editing), Markus Luster(Writing – review & editing), Andreas Pfestroff, Pietro Fazio, Ali Ebrahimifard(Writing – review & editing), Behrooz H. Yousefi, Shamim Bagheri(Writing – review & editing), Friederike Eilsberger(Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Writing – review & editing)
Institutions: Philipps University of Marburg, University of Cologne
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7204271570
